Treatment of leishmaniasis with miltefosine: 2008 status.
about
The Dialogue of the Host-Parasite Relationship: Leishmania spp. and Trypanosoma cruzi InfectionDrug repurposing and human parasitic protozoan diseasesIntrachromosomal amplification, locus deletion and point mutation in the aquaglyceroporin AQP1 gene in antimony resistant Leishmania (Viannia) guyanensisResolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment.Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan.Protein network prediction and topological analysis in Leishmania major as a tool for drug target selection.Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.Update in the treatment of cutaneous leishmaniasis.Design and synthesis of novel antileishmanial compounds.New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.Leishmaniasis in the United States: treatment in 2012Antimicrobial and antiprotozoal activities of secondary metabolites from the fungus Eurotium repens.Advances in Chagas disease drug development: 2009-2010Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.Amphiphilic Antimony(V) Complexes for Oral Treatment of Visceral LeishmaniasisThe reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.Drug delivery systems for the topical treatment of cutaneous leishmaniasis.Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discoveryNew approaches from nanomedicine for treating leishmaniasis.Novel selective inhibitor of Leishmania (Leishmania) amazonensis arginase.Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies.Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.Anticancer agents against malaria: time to revisit?Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases.[Leishmaniasis].Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis
P2860
Q26829884-D6EC19B8-0926-4E7F-AB99-4CF7F178CE0CQ26999453-FB54CE87-7D6A-4E43-BF5F-E49A5447C3F8Q28543469-D14DB0C5-760A-45E4-B31E-9402E4981C90Q33578769-0BE6D24A-746B-4DB5-AE08-93A88CD95A9BQ33603346-EAB00CEC-8AEE-4381-AD60-344ED804520DQ33704536-95BC7DBD-7219-4245-BD1F-6850EEDA4524Q34289958-2DB35319-B468-45D2-B432-AE567FC7711CQ34421618-F7DDC3F6-9B11-44E7-9320-FED538EAC528Q35061244-EFCD0B3E-8AEB-4CA0-B99F-7A0C004987C5Q35219247-868908CD-DAED-4888-9978-F8F66537D1C5Q35771790-2C53F596-78A7-4C05-BB9F-AE1B6500ACD4Q36277777-223616CA-EAB8-4E83-8D5E-BD22CE54779FQ36702159-AD7EF0D0-AC0B-48F7-8E4D-A2469F421CD2Q37053235-7B399A7D-D5CB-4D3A-A542-947CCE63BCB4Q37124150-167F5FFB-7347-430F-BBD9-36F75EB62450Q37425218-ECDA92DA-B9A5-4253-A0A6-8BA83D16AC19Q38020882-DD794E19-6F6D-4B64-9C98-F532B590FA3DQ38291539-F038AA37-9B13-4E4C-B0E3-D9C76A87A0E3Q38612712-50FC7AEE-326B-4134-8183-AF0FD0A3776EQ38890601-AE4644C5-AA8B-4EF0-AAF2-B975115EDE6BQ39311884-A94F400F-D01E-4C7A-BBA2-A45E352DAED3Q41011525-8EBB9D28-0720-4532-956D-1AF32DC10BE1Q42488257-907087EB-7174-4F94-B052-D1A9B61C7DD0Q43037902-8A0FE95E-EDC2-4E2F-BB32-DD688E9FCC3EQ43688298-9D97A054-90A5-4028-B6DD-8656EB9A6539Q45185252-7D7CE74A-56A2-413B-84F9-33A994D6EABDQ59003574-295070D7-DCE7-4DD5-BFEA-C9699A17C0B6
P2860
Treatment of leishmaniasis with miltefosine: 2008 status.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of leishmaniasis with miltefosine: 2008 status.
@en
Treatment of leishmaniasis with miltefosine: 2008 status.
@nl
type
label
Treatment of leishmaniasis with miltefosine: 2008 status.
@en
Treatment of leishmaniasis with miltefosine: 2008 status.
@nl
prefLabel
Treatment of leishmaniasis with miltefosine: 2008 status.
@en
Treatment of leishmaniasis with miltefosine: 2008 status.
@nl
P2860
P1476
Treatment of leishmaniasis with miltefosine: 2008 status.
@en
P2093
Jonathan Josh Berman
P2860
P304
P356
10.1517/17425255.4.9.1209
P407
P577
2008-09-01T00:00:00Z